Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 3/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.81 |
| ▸ | LMNA | P02545 | 1/20 | 0.81 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.69 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.69 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 6/20 | 0.64 |
| ▸ | LPAR1 | Q92633 | 3/20 | 0.64 |
| ▸ | ENPP2 | Q13822 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9716947 | 1.00 | PRKCA (0.85) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL13901084 | 1.00 | PRKCA (0.85) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL1477766 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL383519 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385995 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL11995515 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385481 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL207207 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385978 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ | |
| SCHEMBL385116 | 0.97 | PRKCA (0.80) | PRKCAALDH1A1LMNAPRKCEPRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7585519-B2 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2009-09-08 | — | — | US | disclosed |
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2009-01-22 | — | — | US | disclosed |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2007-08-16 | — | — | US | disclosed |
| EP-1183228-B1 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES USEFUL AS CATIONIC LIPIDS FOR THE INTRACELLULAR DELIVERY OF PHARMACOLOGICALLY ACTIVE COMPOUNDS. | SIGMA TAU IND FARMACEUTI (IT) | 2005-01-12 | — | — | EP | disclosed |
| US-6797281-B1 | Esters of I-carnitine or alkanoyl I-carnitines | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-28 | — | — | US | disclosed |
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2004-09-23 | — | — | US | disclosed |
| EP-1183228-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000061543-A2 | ESTERS OF L-CARNITINE OR ALKANOYL L-CARNITINES | SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P.A. (IT) | 2000-10-19 | — | — | WO | disclosed |
| EP-0445278-A4 | REDUCED CALORIE TRIGLYCERIDES IN FOODS | — | 1992-03-11 | — | — | EP | disclosed |
| EP-0445278-A1 | REDUCED CALORIE TRIGLYCERIDES IN FOODS | NABISCO BRANDS, INC. (US) | 1991-09-11 | — | — | EP | disclosed |
| WO-1991003944-A1 | REDUCED CALORIE TRIGLYCERIDES IN FOODS | NABISCO BRANDS, INC. (US) | 1991-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186175-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CPT1B, SLC25A20, CRAT | PRKCA 1645/4885ALDH1A1 461/4885LMNA 297/4885 |
| US-20070190128-A1 | Esters of L-carnitine or alkanoyl L-carnitines useful as cationic lipids for the intracellular delivery of pharmacologically active compounds | CRAT, SLC25A20, CPT1B | PRKCA 1495/4885ALDH1A1 637/4885LMNA 238/4885 |
| US-20090022729-A1 | METHODS AND COMPOSITIONS FOR TREATING CARDIAC DYSFUNCTIONS | TNNI3, MYLK2, FABP3 | PRKCA 44/4885ALDH1A1 2037/4885LMNA 118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.